Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Summary

This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was conducted in 17 countries, started in 2010 and ended in 2018.

Timeline

Start

2010-03-22

Primary completion

2018-02-27

Completion

2018-02-27

Outcome

Met primary endpoint

registry analysis (other test); Deferasirox vs Placebo; p = 0.015; Hazard Ratio (HR) 0.636 (95% CI 0.42 to 0.96) NCT00940602 ↗

Publications

• Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G; TELESTO Study Investigators. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24.

Drugs

Indications